<DOC>
	<DOCNO>NCT00350337</DOCNO>
	<brief_summary>This descriptive study evaluate safety immunogenicity 3 different formulation WRAIR dengue vaccine compare placebo .</brief_summary>
	<brief_title>A Phase II Trial WRAIR Live Attenuated Virus Tetravalent Dengue Vaccine Healthy US Adults</brief_title>
	<detailed_description>Subjects randomize one 4 group . One group receive placebo vaccine others receive one 3 different dengue vaccine formation . Each subject receive two dos six month apart . Study subject elect participate mosquito transmissibility component study undergo mosquito feeding two assign follow-up visit vaccine dose 1 . All subject 11 venipuncture 11 visit ( i.e. , screen plus 10 study visit ) period nine month . A third ( booster ) dose post transfection F17 F19 administer approximately 5 12 month dose 2 subject receive one formulation first two dos . Volunteers return single visit 6 month receive booster dose ( long term follow-up )</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A healthy male female adult 1845 year time vaccination ; Free obvious health problem establish medical history physical examination enter study ; Written inform consent obtain subject ; Able read Subject Information Sheet Consent Form ; Subjects investigator believe comply requirement protocol ( e.g. , completion diary card , return followup visit ) enrol study ; If subject female , must nonchildbearing potential , i.e . either surgically sterilize one year postmenopausal ; , childbearing potential , must abstinent use adequate contraceptive precaution ( i.e . intrauterine contraceptive device ; oral contraceptive equivalent hormonal contraception , e.g . progestin implantable , cutaneous hormonal patch injectable contraceptive ) 30 day prior vaccination , negative pregnancy test within 48 hour prior vaccination must agree continue precaution 60 day completion vaccination series . Pregnant lactate female ; Female planning become pregnant planning discontinue abstinence contraceptive precaution ; History neurological behavioral disorder seizure , exception single febrile seizure childhood ; History drug abuse alcohol consumption ( 2 drink per day ) ; History allergic disease/reaction likely exacerbate component vaccine ; History urticaria related mosquito bite require medical attention ; Acute chronic , clinically significant pulmonary , cardiovascular , hepatic , renal , hematologic endocrine functional defect , determine physical examination laboratory test ; Any confirm suspected immunosuppressive immunodeficient condition ; Subject seropositive HBsAg , antiHCV antiHIV ; Acute disease time enrollment ( acute disease define presence moderate severe illness without fever ) ; ( Vaccine administer person minor illness diarrhea , mild upper respiratory infection without lowgrade febrile illness , i.e. , oral temperature &lt; 37.5°C/ &lt; 99.5°F . ) Chronic hepatomegaly , right upper quadrant abdominal pain tenderness ; Chronic splenomegaly , leave upper quadrant abdominal pain tenderness ; Use investigational nonregistered drug vaccine study vaccine within 30 day precede study vaccine ( include placebo ) plan use study period ; Planned administration vaccine foreseen study protocol period start 30 day dose study vaccine end 30 day ; A plan move location prohibit participate trial 9 month initial vaccination ; Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within 90 day precede first dose plan administration study period . For corticosteroid , mean prednisone , equivalent , 0.5 mg/kg/day . Inhaled topical steroid allow ; Administration immunoglobulins and/or blood product within 90 day precede first dose plan administration study period ; Any chronic systemic drug therapy continue study period ( except vitamin/mineral supplement , single antihypertension medication routine treatment gastroesophageal reflux ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2008</verification_date>
</DOC>